BioSpace News Archive

Monopar Therapeutics Inc. today announced it is planning to report over the next two months (1) the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, (2) clinical data from its camsirubicin Phase 1b trial, and (3) a preclinical progress update on its MNPR-101 RIT program.

RedHill Biopharma Ltd. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the granting of a patent covering RHB-204’s1 oral fixed-dose combination.

Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the closing of an oversubscribed $49 million Series B financing.

Element Biosciences, Inc announced the promotion of Shawn Levy , PhD, to Chief Scientific Officer and Senior Vice President of Applications.

Elucid, Inc. today announced the addition of Scott Burger as chief commercial officer.

Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch of, and first patient cases involving, the Mariner ® Deformity Pedicle Screw System.

Accuray Incorporated (NASDAQ: ARAY) announced today that the European Radiosurgery Center Munich has selected a second CyberKnife® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers.

Pear Therapeutics, Inc. announced today the expansion of its collaboration with BrightView Health, an addiction treatment provider that offers evidence-based, outpatient addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.

Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor Group”).

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock.